Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service

Senseonics Announces Positive Coverage Decision for Eversense CGM from Highmark Inc.


Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced Highmark Inc. will begin providing coverage for the Eversense CGM effective September 28, 2020. This coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider's time for the in-office sensor placement.

Highmark is among the top 10 largest health insurers in the United States, providing plans to residents across Pennsylvania, West Virginia and Delaware as an independent licensee of the Blue Cross Blue Shield Association. The organization provides plans to over 5.6 million members and is the largest healthcare insurer in Pennsylvania and the fourth-largest overall Blue Cross Blue Shield affiliate.

"Creating access to our CGM technology for diabetes patients through broad-based reimbursement is a priority for ensuring the long-term success of Eversense and our next-generation systems," said Tim Goodnow, PhD, President and CEO of Senseonics. "It is encouraging to see the growing number of healthcare plans that recognize the value of our differentiated long-term implantable system and the benefits it provides to patients. We are pleased with this recent success and with our progress increasing patient access to date."

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://eversensediabetes.com/safety-info/.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.


These press releases may also interest you

at 17:05
Radient Technologies Inc. ("Radient" or the "Company") , announces that the Company will be relying on the temporary 45 day extension to the filing deadline of its financial statements and management's discussion and analysis ("MD&A") for the quarter...

at 17:00
Pike Mountain Minerals Inc. ("Pike" or the "Company") and Carebook Technologies Inc. ("Carebook") announced today that on September 14, 2020, shareholders of Pike approved the previously announced business combination and reverse takeover transaction...

at 17:00
Propel Marketing & Design, Inc., a South Florida based Marketing Agency, is pleased to announce the launch of a new DIY Search Engine Optimization Program specifically designed for chiropractors. This SEO program has been specially and specifically...

at 17:00
Nalu Medical, Inc. ("Nalu"), a global medical device company that provides miniaturized Neuromodulation implants for the treatment of chronic pain via Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), today announced the addition...

at 17:00
OCLI, a state-of-the-art multi-practice ophthalmology group in Long Island, today announced the addition of Lewis Weinstein, MD, a highly experienced, board-certified comprehensive ophthalmologist. On October 5, 2020, he will begin seeing patients at...

at 16:55
Pfizer Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic...



News published on 7 august 2020 at 08:05 and distributed by: